Event at-a-glance
The Immuno-Oncology & Biomarker Summit 2026 organized by Veridon Global is a premier two-day conference bringing together 150+ senior decision-makers from leading pharmaceutical companies, biotech innovators, and academic institutions to accelerate breakthroughs in immunotherapy and biomarker science.
Taking place in London, UK on 12th & 13th March, 2026, this summit serves as a dynamic platform to explore the latest advancements in antibody-drug conjugates (ADCs), bispecific antibodies, cellular therapies, and immune checkpoint inhibitors. It also delves deep into emerging combination strategies, pre-clinical and translational I-O research, and the evolution of personalized and targeted immunotherapy approaches -from early discovery through to late-phase trials.
With a spotlight on biomarker discovery, immune monitoring, vaccine development, and the integration of multi-omic platforms, this event offers a unique opportunity to examine how scientific innovations are reshaping oncology treatment paradigms.
Through cutting-edge content, strategic discussion, and high-level networking, the summit will equip attendees to navigate scientific complexity, improve clinical translation, and drive effective patient outcomes in the next era of immuno-oncology and biomarker discovery.
Key Topics
- Pioneering Immunotherapies in Oncology: ADCs, Bispecific Antibodies, and Cellular Therapies
- Biomarker-Driven Precision Oncology: Translating Discovery to Clinical Impact
- Strategic Combination Therapies: Enhancing Efficacy and Overcoming Resistance
- Biomarker Discovery and Validation: Key to Unlocking Precision Immunotherapy
- Translational Research and Preclinical Models in Immuno-Oncology
- Advancing Cancer Vaccines and Oncolytic Viruses
- Innovative Immune Monitoring Technologies: Real-Time Insights for Better Decision-Making
- Biomarker Integration in Immuno-Oncology Clinical Trials
Why join us?
- Learn from top-tier experts about the latest advancements in immuno-oncology therapies, biomarker discovery, and precision oncology that are shaping the future of cancer treatment.
Network with 150+ senior decision-makers from pharma, biotech, and academia, creating opportunities for partnerships and collaborations in cutting-edge cancer therapies.
Discover how combination immunotherapies, including immune checkpoint inhibitors, ADCs, and cellular therapies, are enhancing treatment outcomes and overcoming resistance.
Dive into how biomarkers are revolutionizing cancer treatment by enabling personalized medicine, improving clinical trial designs, and optimizing patient selection for therapies.
Get up-to-date on the latest global regulatory frameworks for biomarker-based diagnostics and immuno-oncology therapies, helping you navigate the evolving landscape of drug approval and clinical trials.
Target Audience
Academics: University/ Research Institutes/Research Labs
Industry: Pharma / Biopharma (Therapeutic Companies)
From Pharmaceutical, Biopharmaceutical and Academic Institutions:
CEO, CSO, Director, VP, Director, Head, Senior Investigator, Manager, Principal Scientist, Scientist, Team Leader, Group Leader, Professor, Assistant Professor, Lecturer, Researchers working on
Immuno-oncology research and drug development/Cancer Immunotherapy
Biomarker discovery and validation
Development of cellular therapies, ADCs, and bispecific antibodies
Biomarker validation, immune profiling, and translational research in the oncology space
Biomarker-based diagnostics and immuno-oncology therapies
Personalized Cancer Treatment
Drug development strategies, clinical trial management, and commercialization of novel cancer therapies
Investors & Venture Capitalists looking for the latest innovations and emerging trends in oncology therapeutics and biomarker diagnostics
Speakers (TBA)
